This HTML5 document contains 31 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C1031
rdf:type
owl:Class
rdfs:label
Piritrexim
rdfs:subClassOf
nci:C2153 nci:C511
nci:A5
nci:C91407
nci:A8
nci:C63923
nci:P106
Pharmacologic Substance Organic Chemical
nci:P108
Piritrexim
nci:P175
351521
nci:P207
C0054332
nci:P210
72732-56-0
nci:P319
MK2A783ZUT
nci:P322
FDA
nci:P325
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called folate antagonists.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
nci:P329
40070
nci:P330
40070
nci:P350
C17H19N5O2
nci:P366
Piritrexim
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>6-[(2,5-Dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Piritrexim</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Piritrexim</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>DCP</n0:term-source><n0:source-code>50547</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>BW-301U</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>piritrexim</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000045276</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>PIRITREXIM</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>MK2A783ZUT</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>BW 301U</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0351521</n0:source-code></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. (NCI04)</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C1031
n5:hasConcept
n6:M0082845